Remove Drug Development Remove Drug Research Remove Drugs
article thumbnail

Foundery, a new biotech venture firm, sets out to speed early immune drug research

BioPharma Drive: Drug Pricing

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

article thumbnail

In vivo preclinical models for immune-mediated inflammatory disease drug development

Crown Bioscience

Continue reading to learn more about IMIDs and some of the challenges facing the field, and to review some in vivo preclinical models that can be used to guide IMID drug research and development.

Disease 52
article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

The road to developing effective drugs is fraught with both promise and challenge, particularly when it comes to what scientists call "undruggable" targets. The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess.

article thumbnail

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. The two broadest categories of drug development can be separated into the preclinical and clinical research stages.

article thumbnail

eBook: Unlocking Undruggable Targets

DrugBank

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. The Power of Drug Repurposing Explore the immense potential of drug repurposing as a strategy for targeting undruggable targets.

article thumbnail

An Evolving Regulatory Environment for Rare and Orphan Diseases

Advarra

Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. Food and Drug Administration (FDA) approval.

Disease 52
article thumbnail

Product Highlight: DrugBank Data Dictionary

DrugBank

At DrugBank we’re committed to improving your daily research and drug development operations. Data Exploration If you’re venturing into a new area of drug research, the Data Dictionary helps you identify relevant data fields and understand their context.